Related Experiment Video
Updated: Jun 23, 2026

Ambulatory ECG Recording in Mice
Published on: May 28, 2010
Regulated overexpression of the A1-adenosine receptor in mice results in adverse but reversible changes in cardiac
Hajime Funakoshi1, Tung O Chan, Julie C Good
1Center for Translational Medicine, Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA.
Insights
Overexpressing adenosine receptors (ARs) in the heart can cause dilated cardiomyopathy and death. However, delaying A1-AR expression until adulthood reduces but does not eliminate cardiac pathology, offering insights into heart failure.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Adenosine Receptor Signaling
Background:
- Adenosine receptors (ARs), specifically A1-AR and A3-AR, are linked to adenosine-mediated cardioprotection.
- Paradoxically, A1-AR and A3-AR overexpression correlate with altered cardiac phenotypes.
- The temporal dynamics of AR signaling in cardiac remodeling require further investigation.
Purpose of the Study:
- To investigate the temporal relationship between A1-AR signaling and cardiac remodeling.
- To assess the effects of controlled A1-AR overexpression in a cardiac-specific manner.
Main Methods:
- Utilized a cardiac-specific, tetracycline-regulated promoter for controlled A1-AR overexpression in mice.
- Examined phenotypes, survival rates, cardiac function, and gene expression under constitutive and delayed A1-AR induction.
- Assessed the impact of A1-AR induction discontinuation on cardiac dysfunction.
Main Results:
- Constitutive A1-AR overexpression led to dilated cardiomyopathy, reduced ventricular function, decreased heart rate, and death within 6-12 weeks.
- Delayed A1-AR expression until adulthood improved survival (>90% at 30 weeks) and prevented immediate cardiac dysfunction.
- Late A1-AR induction still resulted in mild cardiomyopathy, accelerated hypertrophy, and dilatation under pressure overload, with decreased Akt phosphorylation and fibrosis.
Conclusions:
- Robust, constitutive A1-AR overexpression induces dilated cardiomyopathy.
- Delayed A1-AR expression ameliorates, but does not fully prevent, cardiac pathology.
- The inducible A1-AR mouse model offers insights into adenosine signaling in heart failure and the consequences of selective vs. nonselective AR activation.
Background:
Both the A1- and A3-adenosine receptors (ARs) have been implicated in mediating the cardioprotective effects of adenosine. Paradoxically, overexpression of both A1-AR and A3-AR is associated with changes in the cardiac phenotype. To evaluate the temporal relationship between AR signaling and cardiac remodeling, we studied the effects of controlled overexpression of the A1-AR using a cardiac-specific and tetracycline-transactivating factor-regulated promoter.
Methods And Results:
Constitutive A1-AR overexpression caused the development of cardiac dilatation and death within 6 to 12 weeks. These mice developed diminished ventricular function and decreased heart rate. In contrast, when A1-AR expression was delayed until 3 weeks of age, mice remained phenotypically normal at 6 weeks, and >90% of the mice survived at 30 weeks. However, late induction of A1-AR still caused mild cardiomyopathy at older ages (20 weeks) and accelerated cardiac hypertrophy and the development of dilatation after pressure overload. These changes were accompanied by gene expression changes associated with cardiomyopathy and fibrosis and by decreased Akt phosphorylation. Discontinuation of A1-AR induction mitigated cardiac dysfunction and significantly improved survival rate.
Conclusions:
These data suggest that robust constitutive myocardial A1-AR overexpression induces a dilated cardiomyopathy, whereas delaying A1-AR expression until adulthood ameliorated but did not eliminate the development of cardiac pathology. Thus, the inducible A1-AR transgenic mouse model provides novel insights into the role of adenosine signaling in heart failure and illustrates the potentially deleterious consequences of selective versus nonselective activation of adenosine-signaling pathways in the heart.
Related Concept Videos
Adrenergic Receptors (Adrenoceptors): Classification
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Receptors: ɑ Subtype
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Receptors: β Subtype
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure II: Pathophysiology

